ba0005cabs.oc1.3 | Oral Communications | ECTS2016
Bradbury Steven
, Rennicks Sarah
, Evans Alyson
, del Carmen Basitdas Mary
, Holen Ingunn
, Ottewell Penelope
Background: We have recently identified interleukin 1B (IL-1B) as a potential biomarker for predicting breast cancer patients at increased risk for developing bone metastasis. In mouse models, IL-1B and its receptor (IL-1R1) are upregulated in breast cancer cells that metastasise to bone compared with cells that do not. We have now investigated whether blocking IL-1R with the clinically licensed antagonist, anakinra, might be a potential treatment for breast cancer and bone me...